Collaborative Arrangements and Licensing Agreements (Details) (USD $)
In Millions, unless otherwise specified |
3 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 3 Months Ended | 6 Months Ended | 6 Months Ended | 6 Months Ended | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2012
Xenon Pharmaceuticals Inc.
Development milestones
|
Jun. 30, 2012
Xenon Pharmaceuticals Inc.
Commercialization milestones
|
Jun. 30, 2012
Xenon Pharmaceuticals Inc.
Regulatory milestones
|
Jun. 30, 2012
Xenon Pharmaceuticals Inc.
Pre-specified events
|
Jun. 30, 2012
Collaborations
Biogen Idec
|
Jun. 30, 2012
Collaborations
Biogen Idec
|
Jan. 31, 2012
Collaborations
Biogen Idec
Agreement entered into in January 2012
|
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in January 2012
Phase 2/3
|
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in January 2012
Development milestones
|
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in January 2012
Pre-specified regulatory milestones
|
Jul. 31, 2012
Collaborations
Biogen Idec
Agreement entered into in June 2012
|
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in June 2012
|
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in June 2012
IND-enabling toxicology study
|
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in June 2012
Development milestones
|
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in June 2012
Pre-specified regulatory milestones
|
May 31, 2012
Collaborations
Genzyme Corporation
|
Jun. 30, 2008
Collaborations
Genzyme Corporation
Y
|
Jun. 30, 2012
Collaborations
Genzyme Corporation
|
Jun. 30, 2011
Collaborations
Genzyme Corporation
|
Jun. 30, 2012
Collaborations
Genzyme Corporation
D
|
Jun. 30, 2011
Collaborations
Genzyme Corporation
|
Dec. 31, 2011
Collaborations
Genzyme Corporation
|
Jun. 30, 2012
Collaborations
Genzyme Corporation
Minimum
|
Jun. 30, 2012
Collaborations
Genzyme Corporation
Maximum
|
Jun. 30, 2012
Collaborations
Genzyme Corporation
Commercialization milestones
|
Jun. 30, 2012
Collaborations
Genzyme Corporation
Regulatory milestones
|
Jun. 30, 2012
Collaborations
Genzyme Corporation
Pre-specified events
|
Jun. 30, 2012
Collaborations
Xenon Pharmaceuticals Inc.
Phase 2
|
|
Collaborations | ||||||||||||||||||||||||||||
Maximum value of collaboration agreement | $ 299 | $ 271 | ||||||||||||||||||||||||||
Upfront fee received | 29 | 12 | ||||||||||||||||||||||||||
Maximum amount of payments receivable | 45 | 150 | 59 | 130 | ||||||||||||||||||||||||
Next prospective milestone | 18 | 10 | 25 | 3 | ||||||||||||||||||||||||
Deferred revenue | 25.4 | 25.4 | 7.5 | 7.5 | 27.7 | |||||||||||||||||||||||
Revenue earned | 1.8 | 3.6 | 42.8 | 16.6 | 59.1 | 33.2 | ||||||||||||||||||||||
License fee received | 175 | |||||||||||||||||||||||||||
Equity investment in entity made by strategic alliance partner | 150 | |||||||||||||||||||||||||||
Equity investment in entity made by strategic alliance partner (in shares) | 5 | |||||||||||||||||||||||||||
Percentage profit | 30.00% | 50.00% | ||||||||||||||||||||||||||
Milestone payment received | 25 | |||||||||||||||||||||||||||
Initial development cost contributed | 125 | |||||||||||||||||||||||||||
Period following an acquisition within which collaborator may purchase rights to receive payments (in days) | 180 | |||||||||||||||||||||||||||
Isis stock ownership percentage must be less than this percentage for strategic partner to acquire additional Isis common stock without prior consent | 2.00% | 2.00% | ||||||||||||||||||||||||||
Maximum period additional shares of Isis common stock will not be purchased without consent (in years) | 10 | |||||||||||||||||||||||||||
Premium for which amortization was completed during the period | 100 | |||||||||||||||||||||||||||
License fee for which amortization was completed during the period | 175 | |||||||||||||||||||||||||||
Percent of total revenue | 4.00% | 5.00% | 90.00% | 84.00% | ||||||||||||||||||||||||
Maximum amount of milestone payments receivable under strategic alliance | $ 26 | $ 120 | $ 150 | $ 296 | $ 825 | $ 725 | $ 1,500 |